trending Market Intelligence /marketintelligence/en/news-insights/trending/CPmywdT5LnERlS1o7ukGVg2 content esgSubNav
In This List

Drugmakers seek 'next wave' biotech deals; Bristol-Myers could attract suitors


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Drugmakers seek 'next wave' biotech deals; Bristol-Myers could attract suitors

Here are the editors' top picks for the week ended Jan. 18.

Drug companies chase deals for cell and gene therapies, biotech's 'next wave'

As the market for cell and gene therapies becomes more established and research activity builds, both big pharmaceutical companies and smaller biotechs are seeking to gain ground in what could become a medical arms race.

Bristol-Myers could attract a takeover bid amid Celgene megadeal, analysts say

As Bristol-Myers Squibb Co. moves to take over Celgene Corp. in a blockbuster $74 billion deal, some analysts are speculating that the parent company-to-be might find itself the subject of its own megadeal.

As 1,000 Arkansans removed from Medicaid, Ky. work requirements back in court

Over 18,000 people lost Medicaid eligibility in Arkansas in 2018 due to the state's work requirements program. Opponents to a similar work requirements program in Kentucky filed an amended complaint Jan. 14.

Rising drug prices, shortages fuel growth in hospital drug spending, report says

A new report from the American Hospital Association found that hospital drug spending increased by nearly 20% between fiscal years 2015 and 2017. According to the report, drug shortages and rising drug costs fueled the spending growth.

Pharma dealmakers seeking long-term growth balance pipeline diversity and focus

At 2019's J.P. Morgan Healthcare Conference in San Francisco, executives from the industry's largest players spoke often about this balancing act, reflecting a trend towards portfolio and pipeline diversification within core therapeutic areas.

US FDA shutdown starts taking casualties, interrupting drug marketing plans

Aimmune Therapeutics Inc.'s peanut allergy drug became one of the early casualties of the U.S. Food and Drug Administration's ongoing partial shutdown. The agency also revised its estimates of funds on hand, saying it has about five weeks' worth.

House Oversight Committee targets a dozen drugmakers in pricing probe

True to his word, Rep Elijah Cummings, D-Md., chairman of the House Oversight Committee, opened an investigation into the pricing practices of a dozen drugmakers involving medicines from multiple classes.

US FDA approves fewer innovative medical devices in 2018

The U.S. FDA's approval of innovative medical devices fell from a record high of last year, though the regulator made efforts to ease regulations for other types of products.

Capitol Checkup: Block grant pushback; ACA suit paused; 'Right to Try' tried

Democrats criticized the Trump administration's plan to go around Congress and turn Medicaid into a block-grant program; a federal appeals court judge put a lawsuit challenging the Affordable Care Act on hold in light of the government shutdown.

Eli Lilly's biggest acquisition shows commitment to precision medicine in cancer

Eli Lilly and Co.'s senior vice president of business development Darren Carroll sat down with S&P Global Market Intelligence to discuss the strategy behind the company's newest deal, its biggest ever by value, and where it goes from here.